HLB Pep

HLB Pep develops peptide-based drug candidates, short chains of amino acids engineered to treat diseases, targeting conditions such as cancer, type-two diabetes, metabolic obesity, bacterial infections, viral infections, and ulcerative colitis.

Its pipeline is aimed at addressing unmet patient needs where existing treatments fall short, and its drug candidates are developed in collaboration with domestic and international specialists. Listed on KOSDAQ, Korea's tech and small-cap board, the company's business is built entirely around an early-stage drug pipeline, with multiple candidates holding patents across several major markets.